3,218.50
-3.30
(-0.10%)
As of 3:13:40 PM GMT+5:30. Market Open.
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
111,033,100
105,623,100
94,636,900
84,188,000
78,862,300
Cost of Revenue
28,257,300
27,877,300
28,276,900
25,374,700
22,353,000
Gross Profit
82,775,800
77,745,800
66,360,000
58,813,300
56,509,300
Operating Expense
54,222,300
52,022,300
44,959,800
41,119,900
38,281,600
Operating Income
28,553,500
25,723,500
21,400,200
17,693,400
18,227,700
Net Non Operating Interest Income Expense
-2,640,800
-3,420,800
-3,186,600
-2,479,100
-3,478,700
Pretax Income
26,391,100
23,521,100
18,471,600
12,259,100
15,262,600
Tax Provision
7,767,300
6,957,300
6,019,300
4,487,300
2,743,800
Net Income Common Stockholders
18,623,800
16,563,800
12,452,300
7,771,800
12,518,800
Diluted NI Available to Com Stockholders
18,623,800
16,563,800
12,452,300
7,771,800
12,518,800
Basic EPS
55.03
48.94
36.79
22.96
36.99
Diluted EPS
55.03
48.94
36.79
22.96
36.99
Basic Average Shares
338,432.30
338,445.44
338,445.44
338,445.44
338,445.44
Diluted Average Shares
338,432.30
338,445.44
338,445.44
338,445.44
338,445.44
Total Expenses
82,479,600
79,899,600
73,236,700
66,494,600
60,634,600
Net Income from Continuing & Discontinued Operation
18,623,800
16,563,800
12,452,300
7,771,800
12,518,800
Normalized Income
18,585,834.15
15,906,218.04
12,205,781.63
10,781,968.60
12,394,949.80
Interest Income
--
114,800
147,800
71,500
50,700
Interest Expense
2,746,300
3,526,300
3,322,400
2,529,300
3,508,200
Net Interest Income
-2,640,800
-3,420,800
-3,186,600
-2,479,100
-3,478,700
EBIT
29,137,400
27,047,400
21,794,000
14,788,400
18,770,800
EBITDA
36,980,400
35,000,400
28,814,300
21,407,700
25,343,900
Reconciled Cost of Revenue
28,257,300
27,877,300
28,276,900
25,374,700
22,353,000
Reconciled Depreciation
7,843,000
7,953,000
7,020,300
6,619,300
6,573,100
Net Income from Continuing Operation Net Minority Interest
18,623,800
16,563,800
12,452,300
7,771,800
12,518,800
Total Unusual Items Excluding Goodwill
53,800
933,800
365,700
-4,747,900
151,000
Total Unusual Items
53,800
933,800
365,700
-4,747,900
151,000
Normalized EBITDA
36,926,600
34,066,600
28,448,600
26,155,600
25,192,900
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
15,834.15
276,218.04
119,181.63
-1,737,731.40
27,149.80
3/31/2021 - 7/1/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ZYDUSLIFE.NS Zydus Lifesciences Limited
822.85
-6.83%
NOVARTIND.BO Novartis India Limited
818.95
+0.63%
DIVISLAB.NS Divi's Laboratories Limited
5,754.50
+0.35%
CIPLA.NS Cipla Limited
1,495.30
+0.91%
MANKIND.BO Mankind Pharma Limited
2,512.30
+3.48%
MANKIND.NS Mankind Pharma Limited
2,519.20
+3.84%
GLENMARK.NS Glenmark Pharmaceuticals Limited
1,354.70
-1.61%
RPGLIFE.NS RPG Life Sciences Limited
2,184.80
+0.77%
IPCALAB.NS Ipca Laboratories Limited
1,407.70
+2.90%
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,692.70
-0.72%